The Frequency of SARS-CoV-2 Anti-spike RBD IgG Antibodies in the Fully Vaccinated and Recovered COVID-19 Infected Individuals.
Elshamy, A., Salem, R., Kamel, N., Hussein, M., Younes, S., Marie, O. (2023). The Frequency of SARS-CoV-2 Anti-spike RBD IgG Antibodies in the Fully Vaccinated and Recovered COVID-19 Infected Individuals.. EKB Journal Management System, 3(1), 31-40. doi: 10.21608/aels.2022.176421.1023
Amany Mohamed Elshamy; Reda Salem; Noha Kamel; Mai Hussein; Soha Younes; Ohoud Mohamed Marie. "The Frequency of SARS-CoV-2 Anti-spike RBD IgG Antibodies in the Fully Vaccinated and Recovered COVID-19 Infected Individuals.". EKB Journal Management System, 3, 1, 2023, 31-40. doi: 10.21608/aels.2022.176421.1023
Elshamy, A., Salem, R., Kamel, N., Hussein, M., Younes, S., Marie, O. (2023). 'The Frequency of SARS-CoV-2 Anti-spike RBD IgG Antibodies in the Fully Vaccinated and Recovered COVID-19 Infected Individuals.', EKB Journal Management System, 3(1), pp. 31-40. doi: 10.21608/aels.2022.176421.1023
Elshamy, A., Salem, R., Kamel, N., Hussein, M., Younes, S., Marie, O. The Frequency of SARS-CoV-2 Anti-spike RBD IgG Antibodies in the Fully Vaccinated and Recovered COVID-19 Infected Individuals.. EKB Journal Management System, 2023; 3(1): 31-40. doi: 10.21608/aels.2022.176421.1023

The Frequency of SARS-CoV-2 Anti-spike RBD IgG Antibodies in the Fully Vaccinated and Recovered COVID-19 Infected Individuals.

Advances in Environmental and Life Sciences
Volume 3, Issue 1, January 2023, Page 31-40  XML PDF (942.73 K)
Document Type: Original research articles
DOI: 10.21608/aels.2022.176421.1023
View on SCiNiTO View on SCiNiTO
Authors
Amany Mohamed Elshamy1; Reda Salem2; Noha Kamel email 3; Mai Hussein2; Soha Younes3; Ohoud Mohamed Marieorcid 4
1Medical Laboratory Science Department, High Technology Institute of Applied Health Sciences, Badr Academy, Badr City, Cairo, Egypt.
2Agricultural Genetic Engineering, Research Institute (AGERI), ARC, Giza 12619, Egypt
3Clinical Pathology Department, Faculty of Medicine, Suez Canal University, 4.5 K, Ring Road, Ismailia 41511, Egypt
4Chemistry Department, Faculty of Science, Suez Canal University, Ismailia, Egypt
Abstract
Background: SARS-CoV-2 genome encodes different kinds of structural and nonstructural proteins. The spike structural protein is the prime target for vaccine manufacturing, drug development, and diagnostic assays.

Methods: In this cross-sectional study, we assessed the developed Receptor Binding Domain (RBD) protein in 520 serum samples. The samples were stratified according to vaccine status into two groups: Group 1 consisted of 274 pre-vaccinated samples collected from April to December 2020 (109 were asymptomatic contacted with COVID-19-patients; 100 patients had positive RT-PCR test for SARS-CoV-2 infection, and 65 were convalescent-COVID-19 cases), and group 2 consisted of 246 post-vaccinated participants with or without past-infection recruited from students, coworkers, and staff members from November 2021 to March 2022. Indirect Enzyme-Linked Immunosorbent Assay (ELISA) was performed to evaluate the seroprevalence of the SARS-CoV-2 immunoglobulin G (IgG) across both groups.

Results: The sensitivity and specificity of the RBD-developed protein were 88.4% (95% CI: 84% - 92%) and 100% (95% CI: 88%- 100%), respectively in the pre-vaccinated group. 213 out of 274 of the pre-vaccinated samples were positive. Meanwhile, the RBD-developed protein provided 100% RBD IgG seropositivity in the recovered COVID-19 cases. Moreover, the results were seropositive in all post-vaccinated candidates (n=246) and the results were reliable in 70 negative pre-pandemic sera specimens. Conclusion: The developed S-RBD protein has the potential to be a successful screening method in COVID-19-vaccinated or infected individuals.
Keywords
Keywords: Recombinant Spike RBD protein; SARS-CoV-2; ELISA; Vaccination
Statistics
Article View: 209
PDF Download: 143